Urticaria
MONDO:0005492A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.
Also known as: hives, urticaria, urticaria (disease), Urticarias
165 clinical trials for this condition and its sub-types, 28 tagged with Urticaria itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Urticaria
-
Angioedema 19 trials · 66 incl. sub-types
3 sub-types
- Hereditary angioedema 58 trials · 60 incl. sub-types Sub-types →
- Acquired angioedema 2 trials · 3 incl. sub-types Sub-types →
- Non-histaminic angioedema 2 trials
-
Idiopathic urticaria 0 trials · 66 incl. sub-types
2 sub-types
- Chronic idiopathic urticaria 65 trials
- Acute idiopathic urticaria 1 trial
-
Chronic urticaria 12 trials · 20 incl. sub-types
1 sub-type
- Chronic inducible urticaria 8 trials
-
Physical urticaria 3 trials · 15 incl. sub-types
3 sub-types
- Familial dermatographia 12 trials
- Cholinergic urticaria 2 trials
- Vibratory urticaria 0 trials · 2 incl. sub-types Sub-types →
-
Cold urticaria 10 trials
-
Allergic urticaria 3 trials · 5 incl. sub-types
1 sub-type
- Non-histaminic angioedema 2 trials
-
Cutaneous mastocytosis 1 trial
3 sub-types
- Cutaneous mastocytoma 0 trials Sub-types →
- Diffuse cutaneous mastocytosis 0 trials Sub-types →
- Maculopapular cutaneous mastocytosis 0 trials Sub-types →
-
Urticaria, aquagenic 1 trial
-
Melkersson-Rosenthal syndrome 0 trials
-
Autoimmune urticaria 0 trials
-
Papular urticaria 0 trials
Most studied deeper sub-types
-
New pill could offer relief for chronic hives sufferers
Disease control OngoingThis study tests a new daily pill, remibrutinib, for adults with chronic spontaneous urticaria (long-term hives and itching) that antihistamines don't control well. About 470 participants will receive either remibrutinib, a placebo, or an active control (omalizumab injections) fo…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug aims to tame severe allergies by lowering key antibody
Disease control CancelledThis early-stage study tests a new drug called cizutamig in about 20 adults with IgE-mediated allergies, including food allergies. The main goal is to see if the drug can safely lower IgE levels, which are antibodies that trigger allergic reactions. Researchers will also monitor …
Phase 1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC